Trinity Biotech Provides An Update On The Continued Development Of Its Continuous Glucose Monitor Technology; Says Recent Testing Of This Patented Process Has Confirmed Its Effectiveness In Improving The Performance Of Trinity Biotech's Glucose Biosensor
Trinity Biotech Provides An Update On The Continued Development Of Its Continuous Glucose Monitor Technology; Says Recent Testing Of This Patented Process Has Confirmed Its Effectiveness In Improving The Performance Of Trinity Biotech's Glucose Biosensor
Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today provided an update on the continued development of its glucose biosensor technology. Earlier this year Trinity Biotech was granted a European patent (EP3703565) for a novel method that enhances the performance of an indwelling sensor, such as a glucose biosensor. Recent testing of this patented process has confirmed its effectiveness in improving the performance of Trinity Biotech's glucose biosensor. Trinity Biotech intends to use this breakthrough process to stabilise and improve the functionality of the glucose biosensor in its next generation continuous glucose monitor (CGM) technology.
Trinity Biotech plc（纳斯达克股票代码：TRIB）是一家商业阶段的生物技术公司，专注于人类诊断和糖尿病管理解决方案，包括可穿戴生物传感器，今天介绍了其葡萄糖生物传感器技术持续发展的最新情况。今年早些时候，Trinity Biotech获得了一项欧洲专利（EP3703565），该专利涉及一种增强葡萄糖生物传感器等内住传感器的性能的新方法。最近对这种专利工艺的测试证实了其在改善Trinity Biotech葡萄糖生物传感器的性能方面的有效性。Trinity Biotech打算利用这一突破性工艺来稳定和改善其下一代连续葡萄糖监测（CGM）技术中葡萄糖生物传感器的功能。
CGMs are small patch-like wearable medical devices that use biosensor wires under the skin to measure glucose in real-time. These devices are increasingly popular in diabetes management and health monitoring.
CGM 是类似贴片的小型可穿戴医疗设备，它使用皮肤下的生物传感器线来实时测量葡萄糖。这些设备在糖尿病管理和健康监测中越来越受欢迎。
